Premium
Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review
Author(s) -
Yost Raymond J.,
Haan Bradley J.,
Mangan Kyle C.
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2176
Subject(s) - dosing , medicine , deep vein , thrombosis , anesthesia , therapeutic index , pharmacokinetics , enoxaparin sodium , regimen , surgery , low molecular weight heparin , drug , pharmacology
Dosing of enoxaparin for deep vein thrombosis ( DVT ) prophylaxis in acutely burned patients has been shown to result in anti‐Xa levels below target range. We describe the first case report, to our knowledge, of a severely burned patient who, despite prophylactic dosing of enoxaparin 30 mg subcutaneously twice daily, developed an acute DVT that required high‐dose enoxaparin (100 mg [1.5 mg/kg] subcutaneously every 8 hours) to maintain anti‐Xa levels within the therapeutic range (0.6–1 IU/ml). Pharmacokinetic evaluations were performed using anti‐Xa levels measured throughout the patient's hospital stay to validate the appropriateness of this high‐dose regimen based on established therapeutic anti‐Xa level ranges. These results suggest that routine anti‐Xa level monitoring, regardless of enoxaparin dosing, is necessary for burn patients who are receiving enoxaparin given their hypermetabolic state following injury.